Compare AU
Compare LNAS vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are LNAS and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
LNAS | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 69 | 63 |
Median incremental investment | $1,000.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,412.88 | $1,875.72 |
Average age group | > 35 | 26 - 35 |
Key Summary
LNAS | DRUG | |
|---|---|---|
Strategy | LNAS.AX was created on 2020-07-13 by ETFS. The fund's investment portfolio concentrates primarily on large cap equity. ETFS Ultra Long Nasdaq 100 Hedge Fund (ASX Code: LNAS.AX) is an exchange traded managed fund that aims to provide investors with geared returns that are positively related to the returns of the Nasdaq-100 Index. The fund provides exposure to the Nasdaq-100 Index of between 200% and 275% of its net asset value. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Nasdaq 100 Long Hedge Fund (100 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | |
Top 3 countries | United States (97.15 %) Netherlands (0.92 %) Brazil (0.69 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 1 % | 0.57 % |
Key Summary
LNAS | DRUG | |
|---|---|---|
Issuer | ETFS | BetaShares |
Tracking index | NASDAQ-100 Index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 1 % | 0.57 % |
Price | $11.53 | $8.12 |
Size | $85.456 million | $182.401 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | 18.63 % | 1.90 % |
Market | ASX | ASX |
First listed date | 12/07/2020 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
LNAS | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 69 | 63 |
Median incremental investment | $1,000.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,412.88 | $1,875.72 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
LNAS | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
LNAS | DRUG |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |